局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展

doi:10.19438/j.cjoms.2020.04.018

摘要/Abstract

摘要： 血管瘤是婴幼儿最常见的良性肿瘤。根据部位、大小、范围、深度、分期、对患儿功能和心理的影响等因素不同,以局部外用和系统用药为主,辅以激光或局部药物注射。目前口服普萘洛尔是治疗浅表性血管瘤的一线药物,然而局部外用β受体阻滞剂更易于被患儿家长接受,其使用人数逐步增多。本文就近年来报道的有关β受体阻滞剂治疗婴幼儿血管瘤的研究现状进行综述,为婴幼儿血管瘤的临床治疗提供理论依据。

关键词: 婴幼儿血管瘤, 浅表型, 普萘洛尔, 噻吗洛尔, 局部外用

Abstract: Hemangioma is the most common benign tumor in infants and young children. It is mainly treated by topical and systemic medication, supplemented by laser therapy, depending on the location, size, extent, depth, stage, functional and psychological impact on children. Oral propranolol is currently the first-line treatment for superficial hemangioma. However, topical β-blockers are more likely to be accepted by children's parents, and their use is gradually increasing. This article reviewed the research progress of β-blockers in the treatment of infantile hemangiomas in recent years, with the aim to provide a theoretical basis for the treatment of infantile hemangiomas.

Key words: Infantile hemangioma, Superficial, Propranolol, Timolol, Topical application

中图分类号:

R739.8

顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.

GU Da, HUO Ran, XU Guang-qi, BI Jian-hai, LI Shang-bin. Progress in topical of application β-blockers in the treatment of infantile hemangioma[J]. China J Oral Maxillofac Surg, 2020, 18(4): 375-380.

参考文献

[1] Bowers RE, Graham EA, Tomlinson KM.The natural history of the strawberry nevus[J]. Arch Dermatol, 1960, 82(5): 667-680.
[2] Bauland CG, Luning TH, Smit JM, et al.Untreated hemangiomas: growth pattern and residual lesions[J]. Plast Reconstr Surg, 2011, 127(4): 1643-1648.
[3] Drolet BA, Esterly NB, Frieden IJ.Hemangiomas in children[J]. N Engl J Med, 1999, 341(3): 173-181.
[4] Goelz R, Poets CF.Incidence and treatment of infantile haemangioma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2015, 100(1): F85-91.
[5] Li J, Chen X, Zhao S, et al.Demographic and clinical characteristics and risk factors for infantile hemangioma: a Chinese case-control study[J]. Arch Dermatol, 2011, 147(9): 1049-1056.
[6] Haggstrom AN, Drolet BA, Baselga E, et al.Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics[J]. J Pediatr, 2007, 150(3): 291-294.
[7] Cheng CE, Friedlander SF.Infantile hemangiomas, complications and treatments[J]. Semin Cutan Med Surg, 2016, 35(3): 108-116.
[8] Léauté-Labrèze C, Dumas De La Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[9] Izadpanah A, Izadpanah A, Kanevsky J, et al.Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis[J]. Plast Reconstr Surg, 2013, 131(3): 601-613.
[10] Peppiatt CM, Howarth C, Mobbs P, et al.Bidirectional control of CNS capillary diameter by pericytes[J]. Nature, 2006, 443(7112): 700-704.
[11] Hermann C, Zeiher AM, Dimmeler S.Shear stress inhibits H2O2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase[J]. Arterioscler Thromb Vasc Biol, 1997, 17(12): 3588-3592.
[12] Dimmeler S, Haendeler J, Rippmann V, et al.Shear stress inhibits apoptosis of human endothelial cells[J]. FEBS Lett, 1996, 399(1-2): 71-74.
[13] Wang X, Fang X, Zhou J, et al.Shear stress activation of nuclear receptor PXR in endothelial detoxification[J]. Proc Natl Acad Sci USA, 2013, 110(32): 13174-13179.
[14] Dela Paz NG, Walshe TE, Leach LL, et al.Role of shear-stress-induced VEGF expression in endothelial cell survival[J]. J Cell Sci, 2012, 125(Pt 4): 831-843.
[15] Walshe TE, Dela Paz NG, D'amore PA. The role of shear-induced transforming growth factor-beta signaling in the endothelium[J]. Arterioscler Thromb Vasc Biol, 2013, 33(11): 2608-2617.
[16] Wong A, Hardy KL, Kitajewski AM, et al.Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells[J]. Plast Reconstr Surg, 2012, 130(5): 1012-1021.
[17] Kum JJ, Khan ZA.Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis[J]. Pediatr Res, 2014, 75(3): 381-388.
[18] Madden KS, Szpunar MJ, Brown EB.Beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines[J]. Breast Cancer Res Treat, 2011, 130(3): 747-758.
[19] Iwata J, Sonobe H, Furihata M, et al.High frequency of apoptosis in infantile capillary haemangioma[J]. J Pathol, 1996, 179(4): 403-408.
[20] Mancini AJ, Smoller BR.Proliferation and apoptosis within juvenile capillary hemangiomas[J]. Am J Dermatopathol, 1996, 18(5): 505-514.
[21] Ji Y, Li K, Xiao X, et al.Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells[J]. J Pediatr Surg, 2012, 47(12): 2216-2223.
[22] Chim H, Armijo BS, Miller E, et al.Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A[J]. Ann Surg, 2012, 256(1): 146-156.
[23] Tu JB, Ma RZ, Dong Q, et al.Induction of apoptosis in infantile hemangioma endothelial cells by propranolol[J]. Exp Ther Med, 2013, 6(2): 574-578.
[24] Ji Y, Chen S, Xu C, et al.The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action[J]. Br J Dermatol, 2015, 172(1): 24-32.
[25] Wedgeworth E, Glover M, Irvine AD, et al.Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey[J]. Br J Dermatol, 2016, 174(3): 594-601.
[26] Kunzi-Rapp K.Topical propranolol therapy for infantile hemangiomas[J]. Pediatr Dermatol, 2012, 29(2): 154-159.
[27] Wang L, Xia Y, Zhai Y, et al.Topical propranolol hydrochloride gel for superficial infantile hemangiomas[J]. J Huazhong Univ Sci Technolog Med Sci, 2012, 32(6): 923-926.
[28] Xu G, Lv R, Zhao Z, et al.Topical propranolol for treatment of superficial infantile hemangiomas[J]. J Am Acad Dermatol, 2012, 67(6): 1210-1213.
[29] Price A, Rai S, Mcleod RWJ, et al.Topical propranolol for infantile haemangiomas: a systematic review[J]. J Eur Acad Dermatol Venereol, 2018, 32(12): 2083-2089.
[30] Guo S, Ni N.Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution[J]. Arch Ophthalmol, 2010, 128(2): 255-256.
[31] Khan M, Boyce A, Prieto-Merino D, et al.The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis[J]. Acta Derm Venereol, 2017, 97(10): 1167-1171.
[32] Püttgen K, Lucky A, Adams D, et al.Topical timolol maleate treatment of infantile hemangiomas[J]. Pediatrics, 2016, 138(3): e20160355.
[33] Khunger N, Pahwa M.Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome[J]. Br J Dermatol, 2011, 164(4): 886-888.
[34] Frommelt P, Juern A, Siegel D, et al.Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma[J]. Pediatr Dermatol, 2016, 33(4): 405-414.
[35] Hoeger PH, Harper JI, Baselga E, et al.Treatment of infantile haemangiomas: recommendations of a European expert group[J]. Eur J Pediatr, 2015, 174(7): 855-865.
[36] Ovadia SA, Landy DC, Cohen ER, et al.Local administration of beta-blockers for infantile hemangiomas: a systematic review and meta-analysis[J]. Ann Plast Surg, 2015, 74(2): 256-262.
[37] Chambers CB, Katowitz WR, Katowitz JA, et al.A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas[J]. Ophthal Plast Reconstr Surg, 2012, 28(2): 103-106.
[38] Chakkittakandiyil A, Phillips R, Frieden IJ, et al.Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study[J]. Pediatr Dermatol, 2012, 29(1): 28-31.
[39] Zhou W, He S, Yang Y, et al.Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma[J]. Drug Dev Ind Pharm, 2015, 41(7): 1109-1119.
[40] Shedden AH, Laurence J, Barrish A, et al.Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily[J]. Doc Ophthalmol, 2001, 103(1): 73-79.
[41] Mcmahon P, Oza V, Frieden IJ.Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic"[J]. Pediatr Dermatol, 2012, 29(1): 127-130.
[42] Borok J, Gangar P, Admani S, et al.Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial[J]. Br J Dermatol, 2018, 178(1): e51-e52.
[43] Pope E, Chakkittakandiyil A.Topical timolol gel for infantile hemangiomas: a pilot study[J]. Arch Dermatol, 2010, 146(5): 564-565.
[44] Chan H, Mckay C, Adams S, et al.RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds[J]. Pediatrics, 2013, 131(6): e1739-1747.
[45] Dalla Costa R, Prindaville B.Doing the math: A simple approach to topical timolol dosing for infantile hemangiomas[J]. 2018, 35(2): 276-277.